Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022)

4D Molecular Therapeutics (FDMT) has disclosed Receivables for 4 consecutive years, with $700000.0 as the latest value for Q4 2022.

  • Quarterly Receivables fell 6.29% to $700000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $700000.0 through Dec 2022, down 6.29% year-over-year, with the annual reading at $700000.0 for FY2022, 6.29% down from the prior year.
  • Receivables for Q4 2022 was $700000.0 at 4D Molecular Therapeutics, down from $747000.0 in the prior quarter.
  • The five-year high for Receivables was $1.5 million in Q4 2020, with the low at $700000.0 in Q4 2022.
  • Average Receivables over 4 years is $970200.0, with a median of $791000.0 recorded in 2021.
  • The sharpest move saw Receivables surged 31.85% in 2020, then plummeted 49.73% in 2021.
  • Over 4 years, Receivables stood at $1.1 million in 2019, then skyrocketed by 31.85% to $1.5 million in 2020, then crashed by 49.73% to $747000.0 in 2021, then fell by 6.29% to $700000.0 in 2022.
  • According to Business Quant data, Receivables over the past three periods came in at $700000.0, $747000.0, and $791000.0 for Q4 2022, Q4 2021, and Q3 2021 respectively.